March 2026 in “European journal of ecology, biology and agriculture.” This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.
This study found that innate lymphoid cells-type 1 (ILC1) can induce alopecia areata by disrupting hair follicle immune privilege without the involvement of classical CD8+ T cells.
3 citations
,
September 2024 in “Journal of Microbiology and Biotechnology” This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.
June 2026 in “kerbala journal of pharmaceutical sciences” In this case-control study, individuals with alopecia areata showed significantly elevated levels of inflammatory markers IL-4, IFN-γ, and CRP, as well as reduced serum Folate and Ferritin, suggesting the condition's multifactorial pathophysiology involves immune activation, systemic inflammation, and micronutrient deficiencies.
1 citations
,
January 2025 in “Advances in Wound Care” This study identified dual epithelial and mesenchymal traits in dermal sheath cells during wound repair, suggesting they could be targeted to enhance healing.
